Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, China; School of Public Health, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, China.
J Affect Disord. 2023 Jan 1;320:421-427. doi: 10.1016/j.jad.2022.09.148. Epub 2022 Oct 5.
Risk of suicide attempt, depression, anxiety and seizure and the association with statins is an ongoing debate. We aim to investigate the association between statins and the above neuropsychological outcomes, in specific pre- and post-exposure time windows.
We identified patients aged 40-75 years old who were dispensed a statin between January 1, 2003 and December 31, 2012 from the Hong Kong Clinical Data Analysis & Reporting System (CDARS), an electronic medical records database. Patients with new onset of suicide attempt, depression, anxiety and seizure were derived from the original dataset separately, in a self-controlled case series study design. A non-parametric spline-based self-controlled case series model was built to measure continuous changes of risk.
We identified 396,614 statin users. The risk of each outcome was elevated prior to statin initiation with incidence rate ratios of 1.38 (95 % CI, 1.09-1.74) for suicide attempt, 1.29 (95 % CI, 1.15-1.45) for depression, 1.35 (95 % CI, 1.19-1.53) for anxiety, and 1.45 (95 % CI, 1.21-1.73) for seizure. The incidence rate ratios remained elevated after the initiation of statins during the first 90 and 91-365 days after statin prescription and decreased to the baseline level after 1 year of continuous prescription.
CDARS includes prescription data but not adherence data, which could lead to misclassification of exposure periods.
Our study does not support a direct association between statin use and suicide attempt, depression, anxiety and seizure, whose risks could be explained by cardiovascular events, for which statins were prescribed.
关于他汀类药物与自杀企图、抑郁、焦虑和癫痫发作风险之间的关系一直存在争议。本研究旨在探讨他汀类药物与上述神经心理结局之间的关系,并特别关注暴露前和暴露后的时间窗。
我们从香港临床数据分析与报告系统(CDARS)中确定了 2003 年 1 月 1 日至 2012 年 12 月 31 日期间年龄在 40-75 岁之间服用他汀类药物的患者。从原始数据集分别推导出新发生自杀企图、抑郁、焦虑和癫痫发作的患者,采用自我对照病例系列研究设计。采用非参数样条基于自我对照病例系列模型来衡量风险的连续变化。
我们确定了 396614 名他汀类药物使用者。在开始使用他汀类药物之前,每种结局的风险均升高,自杀企图的发病率比为 1.38(95%可信区间,1.09-1.74),抑郁为 1.29(95%可信区间,1.15-1.45),焦虑为 1.35(95%可信区间,1.19-1.53),癫痫发作为 1.45(95%可信区间,1.21-1.73)。在开始使用他汀类药物后的 90 天和 91-365 天内,发病率比值仍然升高,并且在连续使用他汀类药物 1 年后降至基线水平。
CDARS 仅包含处方数据,不包含药物使用依从性数据,这可能导致暴露期的错误分类。
本研究不支持他汀类药物使用与自杀企图、抑郁、焦虑和癫痫发作之间存在直接关联,他汀类药物的使用是为了预防心血管事件,这些风险可以用心血管事件来解释。